Adding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated ...

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors had a lower risk for rheumatic disease ...

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The use of SGLT2 inhibitors and GLP-1 receptor agonists ...

Use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors rather than metformin as first-line treatment for type 2 diabetes appears to cut the risk for heart failure hospitalization but not myocardial ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

In a recent study published in the journal Signal Transduction and Targeted Therapy, researchers from Australia investigated the potential of small molecule inhibitors, specifically GSK126 (short for ...

Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant ...

Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...

Cancer cells with a cell nucleus that is easily deformed are more sensitive to drugs that damage DNA. These are the findings ...